CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Completed· 10 enrolled
Drug / intervention
Celebrexdrug
Likely dose
Celebrex 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01901679
NCT01901679Early Ph 1Completed
CompareCT.gov

A Pilot Study: Celecoxib Inhibition of Aromatase Expression and Inflammation in Adipose Tissue of Obese Postmenopausal Women

Rockefeller University·interventional·Posted Jul 17, 2013·Updated Feb 1, 2021

In Brief

A Early Phase 1 clinical trial evaluating Celebrex for Obesity. Completed, enrolled 10 participants across 1 site.

Detailed Summary

The study plans to find out whether Celebrex may be potentially useful to decrease inflammation in fat tissues and thereby lower the production of substances such as estrogens that may increase the risk of developing breast cancer and lead to a poor outcome of the disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity
CountriesUnited States
Collaborators--

Timeline

Early Ph 1CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJul 17, 2013
Enrollment StartJul 1, 2013
Primary CompletionAug 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 13.0 years ago

Interventions

Celebrexdrug

200 mg PO BID